The U.S. Food and Drug Administration on Friday granted the drug company Gilead emergency authorization to distribute the drug remdesivir for treatment of COVID-19, a possible flashpoint in the fight against the deadly disease.
President Trump announced the approval on Friday. Remdesivir showed promising results in a clinical trial earlier this week, with at least 50% of participating coronavirus patients showing some improvement with the drug.
The clinical trial did not incorporate a control group as part of the study, although infectious disease expert Dr. Anthony Fauci called the results "quite good news."
Health and Human Services Secretary Alex Azar said in a statement:
"FDA's emergency authorization of remdesivir, two days after the National Institutes of Health's clinical trial showed promising results, is a significant step forward in battling COVID-19 and another example of the Trump Administration moving as quickly as possible to use science to save lives."